Is Revolution Medicines a Good Stock to Own?
Though it’s still quite early in the year, pharmaceutical startup…
Buy
67
ARQT Quote, Financials, Valuation and Earnings
Last price:
$26.33
Seasonality move
:
38.52%
Day range:
$25.77 - $26.93
52-week range:
$11.13 - $31.77
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
10.74x
P/B ratio:
20.71x
Volume:
1.3M
Avg. volume:
2M
1-year change:
101.28%
Market cap:
$3.3B
Revenue:
$196.5M
EPS (TTM):
-$0.35
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$110.8M | $0.08 | 53.91% | -88.43% | $31.63 |
|
ADMA
ADMA Biologics, Inc.
|
$139.8M | $0.20 | 26.61% | 81.82% | $25.67 |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$232.4M | $1.97 | 5.85% | 135.96% | $109.25 |
|
CRMD
CorMedix, Inc.
|
$128.3M | $0.80 | 200.36% | 90.44% | $16.86 |
|
EDIT
Editas Medicine, Inc.
|
$8.5M | -$0.21 | -72.38% | -61.06% | $5.13 |
|
FOLD
Amicus Therapeutics, Inc.
|
$179.8M | $0.16 | 20.08% | 234.42% | $14.83 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$26.73 | $31.63 | $3.3B | -- | $0.00 | 0% | 10.74x |
|
ADMA
ADMA Biologics, Inc.
|
$18.28 | $25.67 | $4.4B | 21.47x | $0.00 | 0% | 9.20x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$85.03 | $109.25 | $1.9B | 52.15x | $0.00 | 0% | 2.08x |
|
CRMD
CorMedix, Inc.
|
$7.09 | $16.86 | $558.6M | 3.45x | $0.00 | 0% | 2.39x |
|
EDIT
Editas Medicine, Inc.
|
$2.22 | $5.13 | $216.7M | -- | $0.00 | 0% | 4.07x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.38 | $14.83 | $4.4B | -- | $0.00 | 0% | 7.36x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ARQT
Arcutis Biotherapeutics, Inc.
|
41.85% | -0.649 | 5.02% | 3.07x |
|
ADMA
ADMA Biologics, Inc.
|
16.16% | -3.305 | 2.38% | 3.53x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
55.53% | -0.736 | 30.7% | 2.40x |
|
CRMD
CorMedix, Inc.
|
1.16% | 2.954 | 0.48% | 1.60x |
|
EDIT
Editas Medicine, Inc.
|
85.41% | 2.863 | 24.32% | 2.81x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | -0.323 | 18.22% | 1.91x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$90.5M | $8.5M | -15.75% | -29.4% | 8.59% | -$1.8M |
|
ADMA
ADMA Biologics, Inc.
|
$75.6M | $51M | 47.04% | 58.71% | 38.01% | -$1.1M |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$111.8M | $22.8M | 3.31% | 8.22% | 10.02% | $37.9M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
EDIT
Editas Medicine, Inc.
|
$6.8M | -$24.5M | -149.99% | -246.73% | -325.44% | -$31.3M |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
Arcutis Biotherapeutics, Inc. vs. Competitors
-
Which has Higher Returns ARQT or ADMA?
ADMA Biologics, Inc. has a net margin of 7.47% compared to Arcutis Biotherapeutics, Inc.'s net margin of 27.14%. Arcutis Biotherapeutics, Inc.'s return on equity of -29.4% beat ADMA Biologics, Inc.'s return on equity of 58.71%.
Company Gross Margin Earnings Per Share Invested Capital ARQTArcutis Biotherapeutics, Inc.91.25% $0.06 $271.8M ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M -
What do Analysts Say About ARQT or ADMA?
Arcutis Biotherapeutics, Inc. has a consensus price target of $31.63, signalling upside risk potential of 18.31%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 40.41%. Given that ADMA Biologics, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe ADMA Biologics, Inc. is more attractive than Arcutis Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARQTArcutis Biotherapeutics, Inc.5 1 0 ADMAADMA Biologics, Inc.3 0 0 -
Is ARQT or ADMA More Risky?
Arcutis Biotherapeutics, Inc. has a beta of 1.710, which suggesting that the stock is 70.962% more volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.466, suggesting its less volatile than the S&P 500 by 53.393%.
-
Which is a Better Dividend Stock ARQT or ADMA?
Arcutis Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcutis Biotherapeutics, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARQT or ADMA?
Arcutis Biotherapeutics, Inc. quarterly revenues are $99.2M, which are smaller than ADMA Biologics, Inc. quarterly revenues of $134.2M. Arcutis Biotherapeutics, Inc.'s net income of $7.4M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Arcutis Biotherapeutics, Inc.'s price-to-earnings ratio is -- while ADMA Biologics, Inc.'s PE ratio is 21.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcutis Biotherapeutics, Inc. is 10.74x versus 9.20x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARQTArcutis Biotherapeutics, Inc.10.74x -- $99.2M $7.4M ADMAADMA Biologics, Inc.9.20x 21.47x $134.2M $36.4M
-
Which has Higher Returns ARQT or ANIP?
ANI Pharmaceuticals, Inc. has a net margin of 7.47% compared to Arcutis Biotherapeutics, Inc.'s net margin of 10.59%. Arcutis Biotherapeutics, Inc.'s return on equity of -29.4% beat ANI Pharmaceuticals, Inc.'s return on equity of 8.22%.
Company Gross Margin Earnings Per Share Invested Capital ARQTArcutis Biotherapeutics, Inc.91.25% $0.06 $271.8M ANIPANI Pharmaceuticals, Inc.49.07% $1.13 $1.1B -
What do Analysts Say About ARQT or ANIP?
Arcutis Biotherapeutics, Inc. has a consensus price target of $31.63, signalling upside risk potential of 18.31%. On the other hand ANI Pharmaceuticals, Inc. has an analysts' consensus of $109.25 which suggests that it could grow by 28.48%. Given that ANI Pharmaceuticals, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe ANI Pharmaceuticals, Inc. is more attractive than Arcutis Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARQTArcutis Biotherapeutics, Inc.5 1 0 ANIPANI Pharmaceuticals, Inc.4 1 0 -
Is ARQT or ANIP More Risky?
Arcutis Biotherapeutics, Inc. has a beta of 1.710, which suggesting that the stock is 70.962% more volatile than S&P 500. In comparison ANI Pharmaceuticals, Inc. has a beta of 0.505, suggesting its less volatile than the S&P 500 by 49.46%.
-
Which is a Better Dividend Stock ARQT or ANIP?
Arcutis Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ANI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcutis Biotherapeutics, Inc. pays -- of its earnings as a dividend. ANI Pharmaceuticals, Inc. pays out 8.77% of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ARQT or ANIP?
Arcutis Biotherapeutics, Inc. quarterly revenues are $99.2M, which are smaller than ANI Pharmaceuticals, Inc. quarterly revenues of $227.8M. Arcutis Biotherapeutics, Inc.'s net income of $7.4M is lower than ANI Pharmaceuticals, Inc.'s net income of $24.1M. Notably, Arcutis Biotherapeutics, Inc.'s price-to-earnings ratio is -- while ANI Pharmaceuticals, Inc.'s PE ratio is 52.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcutis Biotherapeutics, Inc. is 10.74x versus 2.08x for ANI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARQTArcutis Biotherapeutics, Inc.10.74x -- $99.2M $7.4M ANIPANI Pharmaceuticals, Inc.2.08x 52.15x $227.8M $24.1M
-
Which has Higher Returns ARQT or CRMD?
CorMedix, Inc. has a net margin of 7.47% compared to Arcutis Biotherapeutics, Inc.'s net margin of 49.9%. Arcutis Biotherapeutics, Inc.'s return on equity of -29.4% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital ARQTArcutis Biotherapeutics, Inc.91.25% $0.06 $271.8M CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About ARQT or CRMD?
Arcutis Biotherapeutics, Inc. has a consensus price target of $31.63, signalling upside risk potential of 18.31%. On the other hand CorMedix, Inc. has an analysts' consensus of $16.86 which suggests that it could grow by 137.76%. Given that CorMedix, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe CorMedix, Inc. is more attractive than Arcutis Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARQTArcutis Biotherapeutics, Inc.5 1 0 CRMDCorMedix, Inc.4 0 0 -
Is ARQT or CRMD More Risky?
Arcutis Biotherapeutics, Inc. has a beta of 1.710, which suggesting that the stock is 70.962% more volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.358, suggesting its more volatile than the S&P 500 by 35.753%.
-
Which is a Better Dividend Stock ARQT or CRMD?
Arcutis Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcutis Biotherapeutics, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARQT or CRMD?
Arcutis Biotherapeutics, Inc. quarterly revenues are $99.2M, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Arcutis Biotherapeutics, Inc.'s net income of $7.4M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Arcutis Biotherapeutics, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 3.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcutis Biotherapeutics, Inc. is 10.74x versus 2.39x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARQTArcutis Biotherapeutics, Inc.10.74x -- $99.2M $7.4M CRMDCorMedix, Inc.2.39x 3.45x $104.3M $108.6M
-
Which has Higher Returns ARQT or EDIT?
Editas Medicine, Inc. has a net margin of 7.47% compared to Arcutis Biotherapeutics, Inc.'s net margin of -332.98%. Arcutis Biotherapeutics, Inc.'s return on equity of -29.4% beat Editas Medicine, Inc.'s return on equity of -246.73%.
Company Gross Margin Earnings Per Share Invested Capital ARQTArcutis Biotherapeutics, Inc.91.25% $0.06 $271.8M EDITEditas Medicine, Inc.90.44% -$0.28 $92.2M -
What do Analysts Say About ARQT or EDIT?
Arcutis Biotherapeutics, Inc. has a consensus price target of $31.63, signalling upside risk potential of 18.31%. On the other hand Editas Medicine, Inc. has an analysts' consensus of $5.13 which suggests that it could grow by 130.86%. Given that Editas Medicine, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe Editas Medicine, Inc. is more attractive than Arcutis Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARQTArcutis Biotherapeutics, Inc.5 1 0 EDITEditas Medicine, Inc.6 7 0 -
Is ARQT or EDIT More Risky?
Arcutis Biotherapeutics, Inc. has a beta of 1.710, which suggesting that the stock is 70.962% more volatile than S&P 500. In comparison Editas Medicine, Inc. has a beta of 2.164, suggesting its more volatile than the S&P 500 by 116.414%.
-
Which is a Better Dividend Stock ARQT or EDIT?
Arcutis Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Editas Medicine, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcutis Biotherapeutics, Inc. pays -- of its earnings as a dividend. Editas Medicine, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARQT or EDIT?
Arcutis Biotherapeutics, Inc. quarterly revenues are $99.2M, which are larger than Editas Medicine, Inc. quarterly revenues of $7.5M. Arcutis Biotherapeutics, Inc.'s net income of $7.4M is higher than Editas Medicine, Inc.'s net income of -$25.1M. Notably, Arcutis Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Editas Medicine, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcutis Biotherapeutics, Inc. is 10.74x versus 4.07x for Editas Medicine, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARQTArcutis Biotherapeutics, Inc.10.74x -- $99.2M $7.4M EDITEditas Medicine, Inc.4.07x -- $7.5M -$25.1M
-
Which has Higher Returns ARQT or FOLD?
Amicus Therapeutics, Inc. has a net margin of 7.47% compared to Arcutis Biotherapeutics, Inc.'s net margin of 10.24%. Arcutis Biotherapeutics, Inc.'s return on equity of -29.4% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital ARQTArcutis Biotherapeutics, Inc.91.25% $0.06 $271.8M FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About ARQT or FOLD?
Arcutis Biotherapeutics, Inc. has a consensus price target of $31.63, signalling upside risk potential of 18.31%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.83 which suggests that it could grow by 3.15%. Given that Arcutis Biotherapeutics, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Arcutis Biotherapeutics, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARQTArcutis Biotherapeutics, Inc.5 1 0 FOLDAmicus Therapeutics, Inc.2 5 0 -
Is ARQT or FOLD More Risky?
Arcutis Biotherapeutics, Inc. has a beta of 1.710, which suggesting that the stock is 70.962% more volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.417, suggesting its less volatile than the S&P 500 by 58.311%.
-
Which is a Better Dividend Stock ARQT or FOLD?
Arcutis Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcutis Biotherapeutics, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARQT or FOLD?
Arcutis Biotherapeutics, Inc. quarterly revenues are $99.2M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Arcutis Biotherapeutics, Inc.'s net income of $7.4M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Arcutis Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcutis Biotherapeutics, Inc. is 10.74x versus 7.36x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARQTArcutis Biotherapeutics, Inc.10.74x -- $99.2M $7.4M FOLDAmicus Therapeutics, Inc.7.36x -- $169.1M $17.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Has Vistra Stock Gone Up?
Integrated power generation business Vistra (NYSE:VST) surprised investors recently when…
Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
67
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Buy
53
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Buy
80
BNR alert for Jan 15
Burning Rock Biotech Ltd. [BNR] is up 12.55% over the past day.
Sell
37
TCOM alert for Jan 15
Trip.com Group Ltd. [TCOM] is down 2.61% over the past day.
Sell
39
DAVE alert for Jan 15
Dave, Inc. [DAVE] is up 3.6% over the past day.
